Concentrated liquid pharmaceutical formulation of furosemide and method of administering same
A stable, isotonic liquid formulation of furosemide addresses solubility and pH issues, allowing comfortable subcutaneous administration and improved patient compliance.
JP7738696B2Active Publication Date: 2025-09-12SCPHARMACEUTICALS INC
5 Cites 0 Cited by
Patent Information
- Application Number
- JP2024059099
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-31
- Filing Date
- 2024-04-01
- Publication Date
- 2025-09-12
- Estimated Expiration
- 2040-01-30
AI Technical Summary
Technical Problem
Furosemide's oral bioavailability and stability are limited due to solubility and pH issues, necessitating intravenous administration, which requires medical professionals and causes discomfort in subcutaneous administration.
Method used
A liquid pharmaceutical formulation of furosemide with concentrations ranging from 40 mg/mL to 250 mg/mL, pH 6.5 to 8.5, and isotonicity, using pharmaceutically acceptable excipients and buffers like benzyl alcohol, N-methyl-pyrrolidone, and tromethamine to enhance stability and comfort during subcutaneous administration.
Benefits of technology
The formulation provides stable, isotonic, and pH-balanced furosemide solutions for subcutaneous use, minimizing discomfort and enabling patient-friendly administration.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same.SOLUTION: Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art